

Electronic supplementary information (ESI) for

Synthesis of 4-functionalized-1*H*-indoles from 2,3-dihalophenols

Roberto Sanz,* Verónica Guilarte, and Nuria García

Departamento de Química, Área de Química Orgánica, Facultad de Ciencias, Universidad de Burgos, Pza. Misael Bañuelos s/n, 09001-Burgos, Spain

rsd@ubu.es

Index

General information	S1
Experimental procedures and characterization data for synthesized compounds	S2
References	S15
Spectra	S17

General information

All reactions involving air-sensitive compounds were carried out under a N₂ atmosphere in oven-dried glassware with magnetic stirring. Temperatures are reported as bath temperatures. Solvents used in extraction and purification were distilled prior to use. TLC was performed on alumina-backed plates coated with silica gel 60 with F₂₅₄ indicator; the chromatograms were visualized by UV light (254 nm) and/or by staining with a Ce/Mo reagent, anisaldehyde or phosphomolybdic acid solution and subsequent heating. *R_f* values refer to silica gel. Flash column chromatography was carried out on silica gel 60, 230-400 mesh. Melting points were obtained with open capillary tubes and are uncorrected. ¹H NMR spectra were recorded at 400 or 300 MHz. Chemical shifts are reported in ppm from tetramethylsilane with the residual solvent resonance as the internal standard (CHCl₃: δ 7.26). Data are reported as follows: chemical shift, multiplicity (s: singlet, br s: broad singlet, d: doublet, dd: doublet of doublets, dt: doublet of triplets, ddd: doublet of doublet of doublets, t: triplet, t app: apparent triplet, td: triplet of doublets, tdd: triplet of doublet of doublets, q: quartet, m: multiplet), coupling constants (*J* in Hz) and integration. ¹³C NMR spectra were recorded at 100.6 or 75.4 MHz using broadband proton decoupling. Chemical shifts are reported in ppm with the solvent resonance as internal standard (CDCl₃: δ 77.16). Carbon multiplicities were assigned by DEPT techniques. GC-MS analysis and low-resolution electron impact mass spectra (EI-LRMS) were obtained at 70 eV on a mass spectrometer and only the molecular ions and/or base peaks as well as significant peaks in MS are given. High-resolution mass spectrometry (HRMS) was carried out on a mass spectrometer. Infrared spectra were recorded with a FT-IR spectrophotometer. Melting points were measured on a Gallenkamp apparatus using open capillary tubes and are uncorrected. All commercially available reagents were used without purification unless otherwise indicated and were purchased from standard chemical suppliers.

Experimental procedures and characterization data for synthesized compounds

Synthesis of trifluoroacetamides 1:¹

2,2,2-Trifluoro-*N*-(3-fluorophenyl)acetamide (1a): purification by crystallization from hexane afforded **1a** (6.37 g, 77%) as a white solid: 67–69 °C (lit.¹ mp 69–70 °C); ¹H NMR (300 MHz, CDCl₃) δ = 8.38 (br s, 1H), 7.48 (dt, J = 10.2, 2.1 Hz, 1H), 7.34 (td, J = 8.2, 2.1 Hz, 1H), 7.26 (ddd, J = 8.2, 2.1, 1.1 Hz, 1H), 6.95 (tdd, J = 8.2, 2.5, 1.1 Hz, 1H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 162.9 (d, J = 246.6 Hz, C), 155.3 (q, J = 37.8 Hz, C), 136.5 (d, J = 10.6 Hz, C), 130.7 (d, J = 9.2 Hz, CH), 116.2 (d, J = 3.2 Hz, CH), 115.7 (q, J = 288.4 Hz, C), 113.5 (d, J = 21.2 Hz, CH), 108.5 (d, J = 26.6 Hz, CH); EI-LRMS m/z 207 (M⁺, 100), 138 (45), 110 (36), 95 (32), 83 (18).

***N*-(3-Chlorophenyl)-2,2,2-trifluoroacetamide (1b):** purification by crystallization from hexane afforded **1b** (7.15 g, 77%) as a white solid: mp 68–70 °C (lit.² mp 66–68 °C); ¹H NMR (300 MHz, CDCl₃) δ = 8.24 (br s, 1H), 7.66 (t, J = 2.0 Hz, 1H), 7.42 (ddd, J = 8.0, 2.0, 1.1 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.22 (ddd, J = 8.0, 2.0, 1.1 Hz, 1H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 155.3 (d, J = 37.8 Hz, 1H), 136.2 (C), 135.2 (C), 130.5 (CH), 126.7 (CH), 121.0 (CH), 118.8 (CH), 115.7 (d, J = 288.5 Hz, C); EI-LRMS m/z 225 (M⁺+2, 33), 223 (M⁺, 100), 154 (51), 126 (19).

Synthesis of 2,2,2-trifluoro-*N*-(3-fluoro-2-iodophenyl)acetamide (2a):

To a solution of *N,N,N',N'*-tetramethylethylenediamine (4.54 cm³, 30.2 mmol) in anhydrous THF (40 cm³) at –80 °C was added slowly *t*BuLi (20 cm³ of a 1.5M solution in pentane, 30 mmol). After 5 min a solution of **1a** (2.48 g, 12 mmol) in THF (10 cm³) was added dropwise avoiding temperature exceed –70 °C. After 40 min at –80 °C, a solution of iodine in THF (10 cm³) was added dropwise to the reaction mixture. The resulting solution was stirred for 40 min at –80 °C. Then, the reaction mixture was allowed to reach room temperature and quenched with an aqueous solution of Na₂S₂O₃ (10%). The aqueous phase was extracted with Et₂O (3 × 30 cm³), and the combined organic layers were washed with HCl 1M, dried over anhydrous Na₂SO₄, and evaporated under reduced pressure. The crude was purified by column chromatography (hexane/EtOAc, 8/1) on silica gel affording **2a** (2.31 g, 58%) as a white-pale reddish solid: R_f 0.44 (hexane/AcOEt, 6/1); mp 104–106 °C; ¹H NMR (300 MHz, CDCl₃) δ = 8.39 (br s, 1H), 8.05 (d, J = 8.3 Hz, 1H), 7.40 (td, J = 8.3, 2.1 Hz, 1H), 7.01–6.94 (m, 1H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 161.9 (d, J = 245.6 Hz, C), 155.0 (q, J = 37.7 Hz, C), 137.4 (d, J = 3.6 Hz, C), 130.9 (d, J = 8.9 Hz, CH), 117.5 (d, J = 3.1 Hz, CH), 115.7 (q, J = 288.5 Hz, C), 113.3 (d, J = 23.8 Hz, CH), 79.0 (d, J = 28.8 Hz, C); EI-LRMS m/z 333 (M⁺, 53), 206 (100), 186 (26), 137 (13), 109 (22); IR (KBr) 3218, 3061, 1717, 1580, 1548, 1463, 1207, 1165, 788, 733 cm^{–1}; HRMS calcd for C₈H₄F₄INO, 332.9274; found, 332.9283.

Synthesis of 4-fluoro-2-phenyl-1*H*-indole (3a) from 2a:

A mixture of **2a** (169 mg, 0.5 mmol), phenylacetylene (77 mg, 0.75 mmol), PdCl₂(PPh₃)₂ (10 mg, 3 mol%), CuI (5 mg, 5 mol%) and Et₂NH (54 mg, 0.75 mmol) in anhydrous DMA (4 cm³) was heated for 4 h at 80 °C under a nitrogen atmosphere (cyclization was completed as monitored by GC-MS). CH₂Cl₂ (20 cm³) and

water (20 cm³) were added to the cooled reaction mixture. The separated aqueous phase was extracted with CH₂Cl₂ (2 × 20 cm³). The combined organic layers were washed with water (2 × 60 cm³). The organic layer was dried over Na₂SO₄ and concentrated at reduced pressure. The remaining residue was purified by column chromatography (hexane/EtOAc, 8/1) on silica gel affording **3a** (92 mg, 87%) as a brown solid: *R_f* 0.47 (hexane/AcOEt, 4/1); mp 62–64 °C (lit.³ mp 65–67 °C); ¹H NMR (300 MHz, CDCl₃) δ = 8.45 (br s, 1H), 7.70–7.63 (m, 2H), 7.51–7.43 (m, 2H), 7.41–7.33 (m, 1H), 7.21–7.09 (m, 2H), 6.93 (dd, *J* = 2.2, 0.7 Hz, 1H), 6.84 (ddd, *J* = 10.3, 7.4 1.2 Hz, 1H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 156.5 (d, *J* = 246.8 Hz, C), 139.3 (d, *J* = 11.2 Hz, C), 138.0 (C), 131.9 (C), 129.2 (2 × CH), 128.1 (CH), 125.3 (2 × CH), 122.8 (d, *J* = 7.6 Hz, CH), 118.6 (d, *J* = 22.4 Hz, C), 107.1 (d, *J* = 3.6 Hz, CH), 105.1 (d, *J* = 18.9 Hz, CH), 95.8 (CH); HRMS calcd for C₁₄H₁₀FN, 211.0797; found, 211.0787.

General procedure for the synthesis of *O*-2,3-dihalophenyl *N,N*-diethylcarbamates **4**:⁴

*n*BuLi (8.25 cm³ of a 1.6M solution in hexane, 13.2 mmol) was added to a solution of *i*Pr₂NH (1.85 cm³, 13.2 mmol) in THF (40 cm³) at 0 °C. After 30 min at 0 °C, the LDA solution was cooled to –78 °C, and the corresponding 3-halophenyl *N,N*-diethylcarbamate (12 mmol) was added. The resulting solution was stirred for 30 min at –78 °C, and then iodine (3.66 g, 14.4 mmol) was added. After 30 min at low temperature, the reaction mixture was allowed to reach room temperature and quenched with saturated aqueous Na₂S₂O₃. The aqueous phase was extracted with Et₂O (3 × 30 cm³), and the combined organic layers were washed with HCl 1M, dried over anhydrous Na₂SO₄, and evaporated under reduced pressure. The crude was purified by column chromatography (hexane/EtOAc, 5/1) on silica gel affording the title compounds **4**, whose spectroscopic and characterization data have been previously reported.⁴

Procedure for the synthesis of 2,3-dihalophenyl ethers **5a** and **5b**:⁵

To a solution of lithium 2,2,6,6-tetramethylpiperidide (20 mmol, generated from *n*BuLi and 2,2,6,6-tetramethylpiperidine) in dry THF (30 cm³), a solution of *t*Bu₂Zn (22 mmol, generated from *t*BuLi and ZnCl₂) in dry THF (30 cm³) was added at –78 °C, and the reaction mixture was stirred at 0 °C for 30 min. Then, the corresponding 3-haloanisole (10 mmol) was added at –78 °C, the reaction mixture was allowed to reach –45 °C (for X = Cl) or –30 °C (for X = Br), and it was stirred at this temperature overnight. Iodine (17.78 g, 70 mmol) in THF (30 cm³) was added to the reaction mixture and it was stirred at room temperature for 2 h. The reaction was quenched with saturated Na₂S₂O₃, and the aqueous solution was extracted with EtOAc (3 × 15 cm³). The combined organic layers were washed with water (2 × 30 cm³) and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane/EtOAc) to afford the 2,3-dihalophenylethers **5a** and **5b**.

1-Chloro-2-iodo-3-methoxybenzene (5a): purification by column chromatography (hexane/EtOAc, 20/1) on silica gel afforded **5a** (2.23 g, 86%) as a white solid: *R_f* 0.28 (hexane/AcOEt, 20/1); mp 52–54 °C (lit.⁶ mp 53.5 °C); ¹H NMR (300 MHz, CDCl₃) δ = 7.22 (t, *J* = 8.1 Hz, 1H), 7.08 (ddd, *J* = 8.1, 1.3, 0.5 Hz, 1H), 6.67 (dd, *J* = 8.1, 1.3 Hz, 1H), 3.87 (s, 3H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 159.9 (C), 139.8 (C), 129.9 (CH),

121.9 (CH), 108.5 (CH), 91.3 (C), 56.9 (CH₃); EI-LRMS m/z 270 ($M^+ + 2$, 31), 268 (M^+ , 100), 253 (23), 225 (12), 126 (24), 111 (11); HRMS calcd for C₇H₆ClIO, 267.9152; found, 267.9166.

1-Bromo-2-iodo-3-methoxybenzene (5b): purification by column chromatography (hexane/EtOAc, 20/1) on silica gel afforded **5b** (2.60 g, 83%) as a white solid: R_f 0.25 (hexane/AcOEt, 20/1); mp 63–65 °C (lit.^{5b} mp 62.5–64 °C); ¹H NMR (300 MHz, CDCl₃) δ = 7.26 (td, J = 8.0, 1.2 Hz, 1H), 7.18 (dt, J = 8.0, 1.2 Hz, 1H), 6.71 (dd, J = 8.0, 1.2 Hz, 1H), 3.87 (s, 3H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 160.1 (C), 131.2 (C), 130.2 (CH), 125.2 (CH), 108.9 (CH), 94.4 (C), 57.0 (CH₃); EI-LRMS m/z 314 ($M^+ + 2$, 100), 312 (M^+ , 100), 299 (21), 297 (20), 172 (42), 170 (40); HRMS calcd for C₇H₆BrIO, 311.8647; found, 311.8635.

General procedure for the synthesis of *N*-(2,3-dihalophenyl)-2-hidroxy-2-methylpropanamides **8** from **4**:

To a solution of the corresponding 2,3-dihalophenyl *N,N*-diethylcarbamate **4** (1 equiv) in EtOH (10 cm³/mmol) NaOH (10 equiv) was added, and the mixture was refluxed for 5–8 h (completion of the hydrolysis was monitored by GC-MS). After the mixture was cooled to room temperature, most of the EtOH was removed under reduced pressure and the residue was diluted with Et₂O and water. The organic phase was rejected and then, the aqueous solution was carefully neutralized with a HCl 1M solution. The aqueous phase was extracted with Et₂O (3 × 30 cm³), and the combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and evaporated under reduced pressure. Without further purification, the crude phenol **6** was dissolved in anhydrous DMF (2 cm³/mmol) under a nitrogen atmosphere and NaOH (3 equiv) was added to the mixture. After 1 h at room temperature, 2-bromo-2-methylpropanamide (3 equiv) was added and the reaction was stirred for 2 h at room temperature. After complete alkylation of **6** to the corresponding 2-(2,3-dihalophenoxy)-2-methylpropanamide **7** (monitored by GC-MS), NaOH (9 equiv) was added and the mixture was heated at 60 °C for 2 h. The reaction was quenched with H₂O and the corresponding *N*-(2,3-dihalophenyl)-2-hidroxy-2-methylpropanamide **8** was recovered as a solid after filtration.

***N*-(3-Fluoro-2-iodophenyl)-2-hydroxy-2-methylpropanamide (8a):** Reaction of 3-fluoro-2-iodophenyl *N,N*-diethylcarbamate **4a** (674 mg, 2 mmol) according to the general procedure afforded **8a** (536 mg, 83%) as a white solid: mp 95–97 °C; ¹H NMR (300 MHz, CDCl₃) δ = 9.31 (br s, 1H), 8.13 (d, J = 8.3 Hz, 1H), 7.35–7.26 (m, 1H), 6.83 (t, J = 8.3 Hz, 1H), 2.71 (s, 1H), 1.58 (s, 6H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 175.0 (C), 161.8 (d, J = 243.7 Hz, C), 139.8 (d, J = 3.5 Hz, C), 130.5 (d, J = 9.0 Hz, CH), 116.5 (d, J = 2.9 Hz, CH), 111.2 (d, J = 23.8 Hz, CH), 78.1 (d, J = 27.9 Hz, C), 74.7 (C), 28.1 (2 × CH₃); EI-LRMS m/z 323 (M^+ , 27), 265 (33), 237 (100), 138 (19), 59 (81); IR (KBr) 3420, 3368, 3289, 1661, 1462, 1416, 776 cm⁻¹; HRMS calcd for C₁₀H₁₁FINO₂, 322.9819; found, 322.9812.

***N*-(3-Chloro-2-iodophenyl)-2-hydroxy-2-methylpropanamide (8b):** Reaction of 3-chloro-2-iodophenyl *N,N*-diethylcarbamate **4b** (3.53 g, 10 mmol) according to the general procedure afforded **8b** (2.78 g, 82%) as a white solid: mp 113–115 °C; ¹H NMR (300 MHz, CDCl₃) δ = 9.33 (br s, 1H), 8.21 (dd, J = 7.8, 1.5 Hz, 1H), 7.31–7.21 (m, 2H), 2.47 (s, 1H), 1.58 (s, 6H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 175.0 (C), 140.4 (C), 139.1 (C), 129.8 (CH), 125.1 (CH), 118.9 (CH), 95.1 (C), 74.7 (C), 28.0 (2 × CH₃); EI-LRMS m/z 341 ($M^+ + 2$, 3),

339 (M^+ , 8), 281 (10), 253 (62), 194 (15), 154 (24), 59 (100); IR (KBr) 3398, 3291, 1662, 1575, 1539, 1444, 1396, 1126, 776 cm^{-1} ; HRMS calcd for $\text{C}_{10}\text{H}_{11}\text{ClINO}_2$, 338.9523; found, 338.9514.

***N*-(3-Bromo-2-iodophenyl)-2-hydroxy-2-methylpropanamide (8c):** Reaction of 3-bromo-2-iodophenyl *N,N*-diethylcarbamate **4c** (794 mg, 2 mmol) according to the general procedure afforded **8c** (620 mg, 81%) as a white solid: mp 118–120 °C; ^1H NMR (300 MHz, CDCl_3) δ = 9.33 (br s, 1H), 8.23 (dd, J = 8.1, 1.4 Hz, 1H), 7.4 (dd, J = 8.1, 1.4 Hz, 1H), 7.22 (t, J = 8.1 Hz, 1H), 2.55 (s, 1H), 1.57 (s, 6H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 174.9 (C), 140.5 (C), 130.4 (C), 130.1 (CH), 128.5 (CH), 119.4 (CH), 98.2 (C), 74.7 (C), 28.0 (2 \times CH_3); EI-LRMS m/z 385 (M^+ +2, 3), 383 (M^+ , 3), 325 (4), 299 (24), 297 (25), 240 (10), 238 (10), 200 (15), 198 (15), 59 (100); IR (KBr) 3387, 3285, 1652, 1651, 1525, 1392, 776, 693 cm^{-1} ; HRMS calcd for $\text{C}_{10}\text{H}_{11}\text{BrINO}_2$, 382.9018; found, 382.9012.

***N*-(2,3-Diiodophenyl)-2-hydroxy-2-methylpropanamide (8d):** Reaction of 2,3-diiodophenyl *N,N*-diethylcarbamate **4d** (890 mg, 2 mmol) according to the general procedure afforded **8d** (680 mg, 79%) as a white solid: mp 144–146 °C; ^1H NMR (300 MHz, CDCl_3) δ = 9.28 (br s, 1H), 8.24 (dd, J = 8.2, 1.4 Hz, 1H), 7.67 (dd, J = 7.8, 1.4 Hz, 1H), 7.09 (t app, J = 8.0 Hz, 1H), 2.53 (br s, 1H), 1.57 (s, 6H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 175.1 (C), 140.0 (C), 135.4 (CH), 130.4 (CH), 120.2 (CH), 108.8 (C), 104.5 (C), 74.5 (C), 28.0 (2 \times CH_3); EI-LRMS m/z 431 (M^+ , 21), 372 (8), 345 (85), 286 (62), 246 (44), 218 (14), 91 (15), 59 (100); IR (KBr) 3318, 1651, 1568, 1523, 1386, 773 cm^{-1} ; HRMS calcd for $\text{C}_{10}\text{H}_{11}\text{I}_2\text{NO}_2$, 430.8879; found, 430.8873.

General procedure for the synthesis of *N*-(2,3-dihalophenyl)-2-hydroxy-2-methylpropanamides **8** from **5**:

BBr_3 (20 cm^3 of a 1M solution in CH_2Cl_2 , 20 mmol) was added dropwise to a solution of the corresponding anisole **7** (4 mmol) in CH_2Cl_2 (120 cm^3) at -78 °C.⁷ The mixture was allowed to reach room temperature overnight, and then NaHCO_3 (1.68 g, 20 mmol) was added. The resulting mixture was cooled to 0 °C, and MeOH (70 cm^3) was added dropwise. After 30 min at 0 °C, the mixture was warmed to room temperature and stirred for 1 h. Most of the solvent was removed under reduced pressure and the residue was diluted with water and CH_2Cl_2 . The separated aqueous phase was extracted with CH_2Cl_2 (2 \times 30 cm^3). The combined organic layers were dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. Without further purification, the corresponding crude dihalophenol **6** was dissolved in anhydrous DMF (8 cm^3) under a nitrogen atmosphere and NaOH (480 mg, 12 mmol) was added to the mixture. After 1 h at room temperature, 2-bromo-2-methylpropanamide (1.99 g, 12 mmol) was added and the reaction was stirred for 2 h at room temperature. After complete alkylation of **6** to the corresponding 2-(2,3-dihalophenoxy)-2-methylpropanamide **7** (monitored by GC-MS), NaOH (9 equiv) was added and the mixture was heated at 60 °C for 2 h. The reaction was quenched with H_2O and the corresponding *N*-(2,3-dihalophenyl)-2-hydroxy-2-methylpropanamide **8** was recovered as a solid after filtration.

General procedure for the synthesis of 2-alkynyl-3-haloanilides **9** and **10**:

A mixture of the corresponding *N*-(2,3-dihalophenyl)propanamide **8b** or **8c** (1 mmol), alkyne (1.5 mmol), PdCl₂(PPh₃)₂ (21 mg, 0.03 mmol), CuI (9.5 mg, 0.05 mmol) and Et₂NH (110 mg, 1.5 mmol) in anhydrous DMF (4 cm³) was stirred under a nitrogen atmosphere at 40, 50 or 80 °C for the desired time until complete consumption of starting material as monitored by GC-MS (2–6 h). CH₂Cl₂ (20 cm³) and aq HCl (20 cm³ of a 0.5M solution) were added to the cooled reaction mixture. The separated aqueous phase was extracted with CH₂Cl₂ (2 × 20 cm³). The combined organic layers were washed with water (2 × 60 cm³). The organic layer was dried over Na₂SO₄ and concentrated at reduced pressure. The remaining residue was purified by column chromatography on silica gel (hexane/EtOAc, 5/1) to afford the coupled products.

***N*-(3-Chloro-2-(2-phenylethynyl)phenyl)-2-hydroxy-2-methylpropanamide (9a):** Reaction of **8b** (339 mg, 1 mmol) with phenylacetylene (153 mg, 1.5 mmol) for 2 h at 80 °C, according to the general procedure, afforded **9a** (268 mg, 86%) as a white solid: *R_f* 0.36 (hexane/AcOEt, 4/1); mp 139–141 °C; ¹H NMR (300 MHz, CDCl₃) δ = 9.83 (br s, 1H), 8.42 (dd, *J* = 8.2, 1.1 Hz, 1H), 7.65–7.57 (m, 2H), 7.40–7.34 (m, 3H), 7.24 (t, *J* = 8.2 Hz, 1H), 7.15 (dd, *J* = 8.2, 1.1 Hz, 1H), 2.35 (br s, 1H), 1.58 (s, 6H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 174.7 (C), 140.2 (C), 135.7 (C), 131.8 (2 × CH), 129.9 (CH), 129.2 (CH), 128.7 (2 × CH), 124.2 (CH), 122.4 (C), 116.8 (CH), 112.9 (C), 101.7 (C), 81.6 (C), 74.8 (C), 28.1 (2 × CH₃) EI-LRMS *m/z* 315 (M⁺+2, 17), 313 (M⁺, 51), 254 (54), 229 (33), 227 (100), 190 (27), 59 (41); IR (KBr) 3365, 3321, 1665, 1571, 1534, 1452, 759, 692 cm⁻¹; HRMS calcd for C₁₈H₁₆ClNO₂, 313.0870; found, 313.0857.

***N*-(3-Chloro-2-(hex-1-ynyl)phenyl)-2-hydroxy-2-methylpropanamide (9b):** Reaction of **8b** (339 mg, 1 mmol) with 1-hexyne (123 mg, 1.5 mmol) for 2.5 h at 80 °C, according to the general procedure, afforded **9b** (264 mg, 90%) as a pale brown solid: *R_f* 0.26 (hexane/AcOEt, 5/1); mp 66–68 °C; ¹H NMR (300 MHz, CDCl₃) δ = 9.65 (br s, 1H), 8.37 (d, *J* = 8.1 Hz, 1H), 7.24–7.07 (m, 2H), 2.55 (t, *J* = 6.9 Hz, 2H), 2.45 (br s, 1H), 1.70–1.46 (m, 4H), 1.56 (s, 6H), 0.95 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 174.8 (C), 140.2 (C), 135.6 (C), 129.0 (CH), 124.1 (CH), 116.7 (CH), 113.5 (C), 103.7 (C), 74.5 (C), 73.1 (C), 30.7 (CH₂), 28.1 (2 × CH₃), 22.1 (CH₂), 19.6 (CH₂), 13.7 (CH₃); EI-LRMS *m/z* 295 (M⁺+2, 17), 293 (M⁺; 51), 207 (48), 193 (41), 178 (64), 164 (88), 59 (100); IR (KBr) 3419, 3322, 1670, 1572, 1516, 1450, 981 cm⁻¹; HRMS calcd for C₁₆H₂₀ClNO₂, 293.1183; found, 293.1184.

***N*-(3-Chloro-2-(hept-1-ynyl)phenyl)-2-hydroxy-2-methylpropanamide (9c):** Reaction of **8b** (339 mg, 1 mmol) with 1-heptyne (144 mg, 1.5 mmol) for 2.5 h at 80 °C, according to the general procedure, afforded **9c** (249 mg, 81%) as a pale brown solid: *R_f* 0.35 (hexane/AcOEt, 4/1); mp 76–78 °C; ¹H NMR (300 MHz, CDCl₃) δ 9.77 (br s, 1H), 8.32 (dd, *J* = 7.6, 1.8 Hz, 1H), 7.15–7.05 (m, 2H), 3.49 (s, 1H), 2.49 (t, *J* = 7.1 Hz, 2H), 1.68–1.56 (m, 2H), 1.53 (s, 6H), 1.47–1.21 (m, 4H), 0.88 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (75.4 MHz, CDCl₃) δ 175.3 (C), 140.0 (C), 135.6 (C), 128.8 (CH), 124.0 (CH), 116.6 (CH), 113.6 (C), 103.8 (C), 74.2 (C), 73.0 (C), 31.1 (CH₂), 28.2 (CH₂), 27.9 (2 × CH₃), 22.2 (CH₂), 19.7 (CH₂), 14.0 (CH₃); EI-LRMS *m/z* 309 (M⁺+2, 7), 307 (M⁺, 21), 206 (20), 180 (35), 164 (44), 59 (100); IR (KBr) 3311, 2953, 1662, 1569, 1520, 1453, 1139, 790, 731 cm⁻¹; HRMS calcd for C₁₇H₂₂ClNO₂, 307.1339; found, 307.1342.

***N*-(3-Chloro-2-(2-cyclohexenylethynyl)phenyl)-2-hydroxy-2-methylpropanamide (9d):** Reaction of **8b** (339 mg, 1 mmol) with 1-ethynylcyclohexene (159 mg, 1.5 mmol) for 3 h at 80 °C, according to the general procedure, afforded **9d** (254 mg, 80%) as a white solid: R_f 0.34 (hexane/AcOEt, 5/1); mp 145–147 °C; ^1H NMR (300 MHz, CDCl_3) δ = 9.67 (br s, 1H), 8.36 (dd, J = 8.1, 1.3 Hz, 1H), 7.17 (t, J = 8.1 Hz, 1H), 7.10 (dd, J = 8.1, 1.3 Hz, 1H), 6.36–6.30 (m, 1H), 2.80 (s, 1H), 2.30–2.22 (m, 2H), 2.18–2.10 (m, 2H), 1.72–1.57 (m, 4H), 1.55 (s, 6H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 174.9 (C), 139.7 (C), 137.0 (CH), 135.4 (C), 129.2 (CH), 124.1 (CH), 120.3 (C), 116.6 (CH), 113.4 (C), 103.8 (C), 79.0 (C), 74.5 (C), 29.0 (CH_2), 28.0 ($2 \times \text{CH}_3$), 26.0 (CH_2), 22.3 (CH_2), 21.5 (CH_2); EI-LRMS m/z 319 ($\text{M}^+ + 2$, 23), 317 (M^+ , 72), 281 (25), 231 (57), 207 (100), 180 (26), 59 (55); IR (KBr) 3372, 3320, 1652, 1572, 1532, 1450, 1435, 1197, 1184, 778, 725 cm^{-1} ; HRMS calcd for $\text{C}_{18}\text{H}_{20}\text{ClNO}_2$, 317.1183; found, 317.1190.

***N*-(3-Chloro-2-(2-(trimethylsilyl)ethynyl)phenyl)-2-hydroxy-2-methylpropanamide (9e):** Reaction of **8b** (339 mg, 1 mmol) with trimethylsilylacetylene (147 mg, 1.5 mmol) for 5.5 h at 40 °C, according to the general procedure, afforded **9e** (251 mg, 81%) as a pale brown solid: R_f 0.47 (hexane/AcOEt, 4/1); mp 144–146 °C; ^1H NMR (300 MHz, CDCl_3) δ = 9.66 (br s, 1H), 8.37 (dd, J = 8.3, 0.9 Hz, 1H), 7.21 (t, J = 8.3 Hz, 1H), 7.09 (dd, J = 8.3, 0.9 Hz, 1H), 2.60 (br s, 1H), 1.55 (s, 6H), 0.29 (d, J = 0.9 Hz, 9H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 175.0 (C), 140.8 (C), 135.8 (C), 130.0 (CH), 124.1 (CH), 116.8 (CH), 112.8 (C), 108.1 (C), 96.6 (C), 74.6 (C), 28.1 ($2 \times \text{CH}_3$), 0.0 ($3 \times \text{CH}_3$); EI-LRMS m/z 311 ($\text{M}^+ + 2$, 10), 309 (M^+ , 29), 236 (100), 208 (39); HRMS calcd for $\text{C}_{15}\text{H}_{20}\text{ClNO}_2\text{Si}$, 309.0952; found, 309.0951.

***N*-(3-Bromo-2-(2-phenylethynyl)phenyl)-2-hydroxy-2-methylpropanamide (10a):** Reaction of **8c** (383 mg, 1 mmol) with 1-phenylacetylene (153 mg, 1.5 mmol) for 3.5 h at 50 °C, according to the general procedure, afforded **10a** (286 mg, 80%) as a white solid: R_f 0.32 (hexane/AcOEt, 4/1); mp 131–133 °C; ^1H NMR (300 MHz, CDCl_3) δ = 9.86 (br s, 1H), 8.44 (dd, J = 8.2, 1.0 Hz, 1H), 7.63–7.58 (m, 2H), 7.38–7.29 (m, 4H), 7.13 (t, J = 8.2 Hz, 1H), 2.87 (s, 1H), 1.55 (s, 6H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 175.0 (C), 140.1 (C), 131.7 ($2 \times \text{CH}$), 130.1 (CH), 129.2 (CH), 128.6 ($2 \times \text{CH}$), 127.3 (CH), 125.0 (C), 122.3 (C), 117.3 (CH), 115.0 (C), 101.1 (C), 83.4 (C), 74.7 (C), 28.0 ($2 \times \text{CH}_3$); EI-LRMS m/z 359 ($\text{M}^+ + 2$, 62), 357 (M^+ , 62), 300 (60), 298 (58), 273 (100), 271 (100), 191 (60), 165 (53), 59 (83); IR (KBr) 3372, 3312, 1661, 1566, 1532, 1446, 1200, 1131, 752, 726, 689 cm^{-1} ; HRMS calcd for $\text{C}_{18}\text{H}_{16}\text{BrNO}_2$, 357.0364; found, 357.0368.

***N*-(3-Bromo-2-(hex-1-ynyl)phenyl)-2-hydroxy-2-methylpropanamide (10b):** Reaction of **8c** (383 mg, 1 mmol) with 1-hexyne (123 mg, 1.5 mmol) for 3.5 h at 50 °C, according to the general procedure, afforded **10b** (431 mg, 85%) as a pale brown solid: R_f 0.31 (hexane/AcOEt, 4/1); mp 70–72 °C; ^1H NMR (300 MHz, CDCl_3) δ = 9.76 (br s, 1H), 8.36 (dd, J = 8.2, 1.0 Hz, 1H), 7.25 (dd, J = 8.2, 1.0 Hz, 1H), 7.05 (t, J = 8.2 Hz, 1H), 3.42 (s, 1H), 2.50 (t, J = 7.0 Hz, 2H), 1.64–1.43 (m, 4H), 1.52 (s, 6H), 0.91 (t, J = 7.2 Hz, 3H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 175.3 (C), 140.1 (C), 129.2 (CH), 127.2 (CH), 125.0 (C), 117.1 (CH), 115.6 (C), 103.1 (C), 74.8 (C), 74.2 (C), 30.5 (CH_2), 27.9 ($2 \times \text{CH}_3$), 22.1 (CH_2), 19.5 (CH_2), 13.7 (CH_3); EI-LRMS m/z 339 ($\text{M}^+ + 2$, 37), 337 (M^+ , 36), 253 (29), 251 (30), 226 (50), 210 (51), 157 (25), 129 (26), 59 (100); IR (KBr) 3419, 3319, 1673, 1567, 1520, 1427, 980, 729 cm^{-1} ; HRMS calcd for $\text{C}_{16}\text{H}_{20}\text{BrNO}_2$, 337.0677; found, 337.0676.

***N*-(3-Bromo-2-(hept-1-ynyl)phenyl)-2-hydroxy-2-methylpropanamide (10c):** Reaction of **8c** (383 mg, 1 mmol) with 1-heptyne (144 mg, 1.5 mmol) for 3.5 h at 50 °C, according to the general procedure, afforded

10c (277 mg, 79%) as a white solid: R_f 0.30 (hexane/AcOEt, 4/1); mp 79–81 °C; ^1H NMR (300 MHz, CDCl_3) δ 9.78 (s, 1H), 8.35 (dd, J = 8.2, 0.8 Hz, 1H), 7.24 (dd, J = 8.2, 0.8 Hz, 1H), 7.03 (t, J = 8.2 Hz, 1H), 3.58 (s, 1H), 2.47 (t, J = 7.2 Hz, 2H), 1.68–1.57 (m, 2H), 1.52 (s, 6H), 1.49–1.24 (m, 4H), 0.87 (t, J = 7.2 Hz, 3H); ^{13}C NMR (75.4 MHz, CDCl_3) δ 175.4 (C), 140.1 (C), 129.1 (CH), 127.1 (CH), 125.0 (C), 117.1 (CH), 115.6 (C), 103.2 (C), 74.8 (C), 74.2 (C), 31.1 (CH_2), 28.2 (CH_2), 27.8 ($2 \times \text{CH}_3$), 22.2 (CH_2), 19.7 (CH_2), 14.0 (CH_3); EI-LRMS m/z 353 ($\text{M}^+ + 2$, 15), 351 (M^+ , 15), 226 (28), 210 (30), 157 (21), 59 (100); IR (KBr) 3295, 2930, 1661, 1564, 1520, 1449, 1130, 981, 788, 730 cm^{-1} ; HRMS calcd for $\text{C}_{17}\text{H}_{22}\text{BrNO}_2$, 351.0834; found, 351.0822.

***N*-(3-bromo-2-(2-cyclohexenylethynyl)phenyl)-2-hydroxy-2-methylpropanamide (10d)**: Reaction of **8c** (383 mg, 1 mmol) with 1-ethynylcyclohexene (159 mg, 1.5 mmol) for 5 h at 50 °C, according to the general procedure, afforded **10d** (310 mg, 86%) as a white solid: R_f 0.32 (hexane/AcOEt, 4/1); mp 154–156 °C; ^1H NMR (300 MHz, CDCl_3) δ = 9.65 (br s, 1H), 8.42 (dd, J = 8.2, 1.1 Hz, 1H), 7.29 (dd, J = 8.2 Hz, 1.1 Hz, 1H), 7.12 (t, J = 8.2 Hz, 1H), 6.37–6.32 (m, 1H), 2.48 (br s, 1H), 2.32–2.22 (m, 2H), 2.21–2.12 (m, 2H), 1.77–1.58 (m, 4H), 1.56 (s, 6H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 174.8 (C), 139.9 (C), 137.1 (CH), 129.6 (CH), 127.2 (CH), 124.9 (C), 120.4 (C), 117.2 (CH), 115.4 (C), 103.2 (C), 80.9 (C), 74.6 (C), 28.9 (CH_2), 28.1 ($2 \times \text{CH}_3$), 26.0 (CH_2), 22.3 (CH_2), 21.5 (CH_2); EI-LRMS m/z 363 ($\text{M}^+ + 2$, 100), 361 (M^+ , 100), 277 (53), 275 (53), 167 (34), 59 (63); IR (KBr) 3376, 3318, 2929, 1653, 1566, 1530, 1446, 1433, 976, 775, 724 cm^{-1} ; HRMS calcd for $\text{C}_{18}\text{H}_{20}\text{BrNO}_2$, 361.0677; found, 361.0677.

***N*-(3-Bromo-2-(2-(trimethylsilyl)ethynyl)phenyl)-2-hydroxy-2-methylpropanamide (10e)**: Reaction of **8c** (383 mg, 1 mmol) with trimethylsilylacetylene (147 mg, 1.5 mmol) for 3 h at 40 °C, according to the general procedure, and afforded **10e** (251 mg, 71%) as a pale brown solid: R_f 0.39 (hexane/AcOEt, 4/1); mp 150–152 °C; ^1H NMR (300 MHz, CDCl_3) δ = 9.70 (br s, 1H), 8.40 (dt, J = 8.2, 0.9 Hz, 1H), 7.27 (td, J = 8.2, 0.9 Hz, 1H), 7.12 (t, J = 8.2 Hz, 1H), 2.83 (s, 1H), 1.54 (d, J = 0.6 Hz, 6H), 0.28 (d, J = 0.8 Hz, 9H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 175.1 (C), 140.8 (C), 130.3 (CH), 127.2 (CH), 125.0 (C), 117.3 (CH), 114.8 (C), 107.5 (C), 98.3 (C), 74.4 (C), 28.0 ($2 \times \text{CH}_3$), -0.1 ($3 \times \text{CH}_3$); EI-LRMS m/z 355 ($\text{M}^+ + 2$, 28), 353 (M^+ , 27), 282 (100), 280 (100), 254 (37), 252 (37), 238 (19), 236 (18); HRMS calcd for $\text{C}_{15}\text{H}_{20}\text{BrNO}_2\text{Si}$, 353.0447; found, 353.0450.

***N*-(3-Bromo-2-(2-(thiophen-3-yl)ethynyl)phenyl)-2-hydroxy-2-methylpropanamide (10f)**: Reaction of **8c** (383 mg, 1 mmol) with 3-ethynylthiophene (162 mg, 1.5 mmol) for 3.5 h at 50 °C, according to the general procedure, afforded **10f** (269 mg, 74%) as a white solid: R_f 0.37 (hexane/AcOEt, 4/1); mp 132–134 °C; ^1H NMR (400 MHz, CDCl_3) δ = 9.82 (br s, 1H), 8.41 (d, J = 8.3 Hz, 1H), 7.63 (dd, J = 2.9, 1.1 Hz, 1H), 7.31–7.27 (m, 2H), 7.24 (dd, J = 4.9, 1.1 Hz, 1H), 7.11 (t, J = 8.3 Hz, 1H), 2.90 (s, 1H), 1.53 (s, 6H); ^{13}C NMR (100.8 MHz, CDCl_3) δ = 175.0 (C), 140.1 (C), 130.0 (CH), 129.9 (CH), 129.8 (CH), 127.3 (CH), 125.9 (CH), 124.7 (C), 121.4 (C), 117.3 (CH), 115.1 (C), 96.3 (C), 83.1 (C), 74.7 (C), 28.0 ($2 \times \text{CH}_3$); EI-LRMS m/z 365 ($\text{M}^+ + 2$, 40), 363 (M^+ , 44), 305 (19), 279 (61), 277 (59), 226 (14), 198 (29), 196 (32), 171 (23), 59 (100); HRMS calcd for $\text{C}_{16}\text{H}_{14}\text{BrNO}_2\text{S}$, 362.9929; found, 362.9928.

General procedure for the synthesis of 4-halo-1*H*-indoles **11** and **12** from anilides **9** and **10**:

To a solution of the corresponding 2-alkynyl-3-haloanilide **9** or **10** (1 equiv) in anhydrous DMF (4 cm³/mmol) freshly powdered NaOH (3 equiv) was added. The resulting mixture was refluxed under a nitrogen atmosphere at 140 °C until the cyclization was completed (as monitored by GC-MS). CH₂Cl₂ (10 cm³) and aq HCl (10 cm³ of a 0.5M solution) were added to the cooled reaction mixture. The separated aqueous phase was extracted with CH₂Cl₂ (2 × 10 cm³). The combined organic layers were washed with water (2 × 30 cm³), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (hexane/EtOAc) to afford the corresponding 4-haloindole **11** or **12**.

4-Chloro-2-phenyl-1*H*-indole (11a): From **9a** (94 mg, 0.3 mmol) and NaOH (36 mg, 0.9 mmol) according to the general procedure (4 h), and purification by column chromatography (hexane/EtOAc, 7/1) on silica gel afforded **11a** (54 mg, 79%) as a white solid: *R*_f 0.32 (hexane/AcOEt, 6/1); mp 73–75 °C (lit.⁸ mp 74–77 °C); ¹H NMR (300 MHz, CDCl₃) δ = 8.43 (br s, 1H), 7.70–7.63 (m, 2H), 7.50–7.43 (m, 2H), 7.39–7.33 (m, 1H), 7.31–7.27 (m, 1H), 7.17–7.08 (m, 2H), 6.94 (dd, *J* = 2.2, 0.8 Hz, 1H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 138.6 (C), 137.4 (C), 131.8 (C), 129.2 (2 × CH), 128.3 (CH), 128.2 (C), 125.9 (C), 125.4 (2 × CH), 122.9 (CH), 120.1 (CH), 109.6 (CH), 98.5 (CH); EI-LRMS *m/z* 229 (M⁺+2, 33), 227 (M⁺, 100), 191 (10), 165 (16), 113 (10); IR (KBr) 3449, 2961, 2924, 1452, 1261, 1098, 803, 756, 688 cm⁻¹; HRMS calcd for C₁₄H₁₀ClN, 227.0502; found, 227.0501.

2-Butyl-4-chloro-1*H*-indole (11b): From **9b** (88 mg, 0.3 mmol) and NaOH (36 mg, 0.9 mmol) according to the general procedure (2.5 h), and purification by column chromatography (hexane/EtOAc, 8/1) on silica gel afforded **11b** (53 mg, 86%) as a colourless oil: *R*_f 0.46 (hexane/EtOAc, 6/1); ¹H NMR (300 MHz, CDCl₃) δ = 7.90 (br s, 1H), 7.18 (dt, *J* = 7.7, 1.0 Hz, 1H), 7.12 (dd, *J* = 7.6, 1.1 Hz, 1H), 7.05 (t, *J* = 7.7 Hz, 1H), 6.38 (dd, *J* = 2.2, 0.9 Hz, 1H), 2.74 (t, *J* = 7.6 Hz, 2H), 1.77–1.66 (m, 2H), 1.51–1.38 (m, 2H), 0.99 (t, *J* = 7.3, 3H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 141.0 (C), 136.5 (C), 127.6 (C), 125.0 (C), 121.6 (CH), 119.4 (CH), 109.1 (CH), 98.1 (CH), 31.2 (CH₂), 28.0 (CH₂), 22.5 (CH₂), 14.0 (CH₃); EI-LRMS *m/z* 209 (M⁺+2, 10), 207 (M⁺, 33), 164 (100), 128 (8), 101 (6); IR (KBr) 3417, 2957, 2929, 1575, 1548, 1433, 1330, 1182, 941, 765 cm⁻¹; HRMS calcd for C₁₂H₁₄ClN, 207.0815; found, 207.0822.

4-Chloro-2-pentyl-1*H*-indole (11c): From **9c** (154 mg, 0.5 mmol) and NaOH (60 mg, 1.5 mmol) according to the general procedure (2.5 h) and purification by column chromatography (hexane/EtOAc, 7/1) on silica gel afforded **11c** (93 mg, 84%) as a pale brown solid: *R*_f 0.46 (hexane/AcOEt, 5/1); mp 24–26 °C; ¹H NMR (300 MHz, CDCl₃) δ = 7.96 (br s, 1H), 7.19 (dd, *J* = 7.6, 0.9 Hz, 1H), 7.11–7.00 (m, 2H), 6.36 (d, *J* = 0.9 Hz, 1H), 2.75 (t, *J* = 7.6 Hz, 2H), 1.79–1.68 (m, 2H), 1.43–1.25 (m, 4H), 0.93 (t, *J* = 6.7 Hz, 3H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 141.0 (C), 136.5 (C), 127.7 (C), 125.0 (C), 121.6 (CH), 119.4 (CH), 109.0 (CH), 98.1 (CH), 31.6 (CH₂), 28.8 (CH₂), 28.3 (CH₂), 22.6 (CH₂), 14.1 (CH₃); EI-LRMS *m/z* 223 (M⁺+2 11), 221, (M⁺, 34), 178 (24), 164 (100), 128 (9), 101 (6); IR (KBr) 3417, 2956, 2928, 1547, 1433, 1329, 1182, 939, 765 cm⁻¹; HRMS calcd for C₁₃H₁₆ClN, 221.0971; found, 221.0980.

4-Chloro-2-cyclohexenyl-1*H*-indole (11d): From **9d** (94 mg, 0.3 mmol) and NaOH (36 mg, 0.9 mmol) according to the general procedure (2.5 h), and purification by column chromatography (hexane/EtOAc, 8/1) on silica gel afforded **11d** (56 mg, 81%) as a pale brown oil: *R*_f 0.70 (hexane/EtOAc, 6/1); ¹H NMR (300

MHz, CDCl₃) δ = 8.21 (br s, 1H), 7.21–7.17 (m, 1H), 7.09–7.02 (m, 2H), 6.54 (d, J = 2.0 Hz, 1H), 6.17–6.12 (m, 1H), 2.51–2.44 (m, 2H), 2.29–2.21 (m, 2H), 1.85–1.76 (m, 2H), 1.75–1.65 (m, 2H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 140.1 (C), 136.8 (C), 128.8 (C), 127.8 (C), 125.6 (C), 123.8 (CH), 122.5 (CH), 119.5 (CH), 109.1 (CH), 97.1 (CH), 26.0 (CH₂), 25.6 (CH₂), 22.5 (CH₂), 22.2 (CH₂); EI-LRMS m/z 233 (M^+ +2, 32), 231 (M^+ , 100), 203 (35), 164 (34), 151 (29); IR (neat) 3433, 2928, 1569, 1432, 1334, 1184, 947, 764, 731 cm⁻¹; HRMS calcd for C₁₄H₁₄ClN, 231.0815; found, 231.0814.

4-Chloro-1H-indole (11e):⁹ From **9e** (168 mg, 0.5 mmol) and NaOH (60 mg, 1.5 mmol) according to the general procedure (4 h), and purification by flash column chromatography (hexane/EtOAc, 8/1) on silica gel afforded **11e** (55 mg, 73%) as a brown oil: R_f 0.33 (hexane/AcOEt, 5/1); ¹H NMR (300 MHz, CDCl₃) δ = 8.25 (br s, 1H), 7.31–7.21 (m, 2H), 7.16–7.08 (m, 2H), 6.70–6.62 (m, 1H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 136.6 (C), 126.9 (C), 126.2 (C), 124.9 (CH), 122.7 (CH), 119.7 (CH), 109.8 (CH), 101.4 (CH); EI-LRMS m/z 153 (M^+ +2, 31), 151 (M^+ , 100), 116 (18), 89 (27).

4-Bromo-2-phenyl-1H-indole (12a): From **10a** (178 mg, 0.5 mmol) and NaOH (60 mg, 1.5 mmol) according to the general procedure (5 h), and purification by flash column chromatography (hexane/EtOAc, 10/1) on silica gel afforded **12a** (113 mg, 83%) as a white solid: R_f 0.38 (hexane/AcOEt, 5/1); mp 100–102 °C; ¹H NMR (300 MHz, CDCl₃) δ = 8.42 (br s, 1H), 7.65 (dd, J = 8.4, 1.0 Hz, 2H), 7.49–7.42 (m, 2H), 7.40–7.29 (m, 3H), 7.06 (t, J = 7.9 Hz, 1H), 6.91–6.89 (m, 1H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 138.5 (C), 137.0 (C), 131.7 (C), 130.1 (C), 129.2 (2 × CH), 128.3 (CH), 125.3 (2 × CH), 123.2 (CH), 114.6 (C), 110.2 (CH), 100.2 (CH); EI-LRMS m/z 273 (M^+ +2, 98), 271 (M^+ , 100), 191 (27), 165 (34), 136 (11); IR (KBr) 3445, 1475, 1452, 1352, 1289, 1181, 916, 758, 691 cm⁻¹; HRMS calcd for C₁₄H₁₀BrN, 270.9997; found, 270.9995.

4-Bromo-2-butyl-1H-indole (12b): From **10b** (101 mg, 0.3 mmol) and NaOH (36 mg, 0.9 mmol) according to the general procedure (3 h), and purification by column chromatography (hexane/EtOAc, 7/1) on silica gel afforded **12b** (61 mg, 80%) as a white solid: R_f 0.45 (hexane/AcOEt, 5/1); mp 29–31 °C; ¹H NMR (300 MHz, CDCl₃) δ = 7.95 (br s, 1H), 7.26 (dd, J = 7.6, 0.8 Hz, 1H), 7.22 (dt, J = 8.0, 0.8 Hz, 1H), 6.99 (t, J = 7.8 Hz, 1H), 6.32 (dd, J = 2.2, 0.9 Hz, 1H), 2.74 (t, J = 7.6 Hz, 2H), 1.77–1.66 (m, 2H), 1.50–1.37 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 141.0 (C), 136.0 (C), 129.6 (C), 122.5 (CH), 121.9 (CH), 113.7 (C), 109.6 (CH), 99.8 (CH), 31.2 (CH₂), 28.0 (CH₂), 22.5 (CH₂), 14.0 (CH₃); EI-LRMS m/z 253 (M^+ +2, 37), 251 (M^+ , 37), 210 (100), 208 (98), 129 (32); IR (KBr) 3407, 2958, 2929, 1539, 1430, 1329, 1178, 917, 763, 729 cm⁻¹; HRMS calcd for C₁₂H₁₄BrN, 251.0310; found, 251.0309.

4-Bromo-2-pentyl-1H-indole (12c): From **10c** (123 mg, 0.35 mmol) and NaOH (42 mg, 1.05 mmol) according to the general procedure (2.5 h) and purification by column chromatography (hexane/EtOAc, 7/1) on silica gel afforded **12c** (76 mg, 82%) as a pale brown oil: R_f 0.42 (hexane/EtOAc, 6/1); ¹H NMR (300 MHz, CDCl₃) δ = 7.97 (br s, 1H), 7.28–7.20 (m, 2H), 6.98 (t, J = 8.0 Hz, 1H), 6.31 (dd, J = 2.2, 0.8 Hz, 1H), 2.74 (t, J = 7.7 Hz, 2H), 1.79–1.68 (m, 2H), 1.43–1.34 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 141.0 (C), 136.1 (C), 129.6 (C), 122.5 (CH), 121.9 (CH), 113.7 (C), 109.6 (CH), 99.9 (CH), 31.6 (CH₂), 28.9 (CH₂), 28.3 (CH₂), 22.6 (CH₂), 14.1 (CH₃); EI-LRMS m/z 267 (M^+ +2, 41), 265 (M^+ , 42), 224

(19), 210 (100), 208 (98), 129 (32); IR (KBr) 3411, 2956, 2928, 1548, 1430, 1327, 1178, 917, 763 cm^{-1} ; HRMS calcd for $\text{C}_{13}\text{H}_{16}\text{BrN}$, 265.0466; found, 265.0467

4-Bromo-2-cyclohexenyl-1H-indole (12d): From **10d** (180 mg, 0.5 mmol) and NaOH (60 mg, 1.5 mmol) according to the general procedure (4 h), and purification by flash column chromatography (hexane/EtOAc, 10/1) on silica gel afforded **12d** (105 mg, 76%) as a colourless oil: R_f 0.50 (hexane/EtOAc, 6/1); ^1H NMR (300 MHz, CDCl_3) δ = 8.27 (br s, 1H), 7.27–7.20 (m, 2H), 6.99 (t, J = 7.8 Hz, 1H), 6.48 (d, J = 1.9 Hz, 1H), 6.17–6.12 (m, 1H), 2.51–2.43 (m, 2H), 2.28–2.20 (m, 2H), 1.84–1.75 (m, 2H), 1.75–1.65 (m, 2H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 140.2 (C), 136.4 (C), 129.7 (C), 128.9 (C), 123.8 (CH), 122.8 (CH), 122.7 (CH), 114.3 (C), 109.7 (CH), 98.9 (CH), 26.1 (CH_2), 25.6 (CH_2), 22.6 (CH_2), 22.2 (CH_2); EI-LRMS m/z 277 ($\text{M}^+ + 2$, 98), 275 (M^+ , 100), 247 (24), 195 (23), 167 (38); IR (KBr) 3427, 2927, 1568, 1524, 1429, 1332, 1179, 917, 762, 730 cm^{-1} ; HRMS calcd for $\text{C}_{14}\text{H}_{14}\text{BrN}$, 275.0310; found, 275.0314.

4-Bromo-1H-indole (12e):⁹ From **10e** (176 mg, 0.5 mmol) and NaOH (60 mg, 1.5 mmol) according to the general procedure (5 h), and purification by flash column chromatography (hexane/EtOAc, 10/1) on silica gel afforded **12e** (73 mg, 75%) as a colourless oil: R_f 0.29 (hexane/EtOAc, 6/1); ^1H NMR (300 MHz, CDCl_3) δ = 8.28 (br s, 1H), 7.37–7.23 (m, 3H), 7.06 (t, J = 7.9 Hz, 1H), 6.64–6.60 (m, 1H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 136.1 (C), 128.8 (C), 124.8 (CH), 123.0 (CH), 122.9 (CH), 114.9 (C), 110.4 (CH), 103.2 (CH); EI-LRMS m/z 197 ($\text{M}^+ + 2$, 100), 195 (M^+ , 100), 184 (7), 116 (77), 89 (44); HRMS calcd for $\text{C}_8\text{H}_6\text{BrN}$, 194.9684; found, 194.9679.

4-Bromo-2-(thiophen-3-yl)-1H-indole (12f): From **10f** (181 mg, 0.5 mmol) and NaOH (60 mg, 1.5 mmol) according to the general procedure (3 h), and purification by flash column chromatography (hexane/EtOAc, 10/1) on silica gel afforded **12f** (99 mg, 71%) as a pale brown solid: R_f 0.48 (hexane/AcOEt, 4/1); mp 44–46 °C; ^1H NMR (300 MHz, CDCl_3) δ = 8.35 (br s, 1H), 7.47–7.38 (m, 3H), 7.29 (d, J = 7.7 Hz, 2H), 7.07–7.00 (m, 1H), 6.75 (d, J = 2.1 Hz, 1H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 136.6 (C), 134.6 (C), 133.5 (C), 129.9 (C), 127.0 (CH), 125.7 (CH), 123.25 (CH), 123.19 (CH), 119.9 (CH), 114.5 (C), 110.0 (CH), 100.2 (CH); EI-LRMS m/z 281 ($\text{M}^+ + 2$, 100), 279 (M^+ , 96), 198 (38), 171 (61), 154 (27), 126 (32); HRMS calcd for $\text{C}_{12}\text{H}_8\text{BrNS}$, 276.9561; found, 276.9576.

General procedure for the synthesis of 4-halo-1H-indoles **3**, **11** and **12** from 2,3-dihaloanilides **8** (one pot procedure):

A mixture of the corresponding *N*-(3-halo-2-iodophenyl)-2-hydroxy-2-methylpropanamide **8** (1 equiv), alkyne (1.5 equiv), $\text{PdCl}_2(\text{PPh}_3)_2$ (3 mol%), CuI (5 mol%) and Et_2NH (1.5 equiv) in anhydrous DMA (4 cm^3/mol) was stirred under a nitrogen atmosphere at 80 °C (for **8a** and **8b**), at 50 °C (for **8c**), or at 40 °C (when trimethylsilylacetylene is used as alkyne) until complete consumption of starting material **8** as monitored by GC-MS (2–5 h). Then, freshly powdered NaOH (10 equiv) was added to the reaction mixture and it was refluxed under a nitrogen atmosphere at 140 °C until the cyclization was completed (3–4 h, as monitored by GC-MS). After cooling of the reaction mixture, CH_2Cl_2 (20 cm^3) and aq HCl (20 cm^3 of a 0.5M solution) were added. The separated aqueous phase was extracted with CH_2Cl_2 (2 \times 20 cm^3) and the combined organic layers were washed with water (2 \times 60 cm^3). The organic layer was dried over anhydrous Na_2SO_4 and concentrated

under reduced pressure. The remaining residue was purified by column chromatography on silica gel (hexane/EtOAc) to afford the corresponding 4-halo-1*H*-indoles **3**, **11** and **12**.

4-Fluoro-2-phenyl-1*H*-indole (3a): Treatment of **8a** (161 mg, 0.5 mmol) with phenylacetylene (77 mg, 0.75 mmol), PdCl₂(PPh₃)₂ (10 mg, 3 mol%), CuI (5 mg, 5 mol%) and Et₂NH (54 mg, 0.75 mmol) in DMA (2 mL) for 3 h and then, with NaOH (200 mg, 5 mmol) for 4 h according to the general procedure, and purification by column chromatography (hexane/EtOAc, 8/1) on silica gel afforded **3a** (90 mg, 85%), whose spectroscopic data have been reported above.

2-Butyl-4-fluoro-1*H*-indole (3b): Treatment of **8a** (161 mg, 0.5 mmol) with 1-hexyne (62 mg, 0.75 mmol), PdCl₂(PPh₃)₂ (10 mg, 3 mol%), CuI (5 mg, 5 mol%) and Et₂NH (54 mg, 0.75 mmol) in DMA (2 mL) for 3 h and then, with NaOH (200 mg, 5 mmol) for 3 h according to the general procedure, and purification by column chromatography (hexane/EtOAc, 8/1) on silica gel afforded **3b** (74 mg, 77%) as a pale brown oil: *R*_f 0.50 (hexane/EtOAc, 4/1); ¹H NMR (300 MHz, CDCl₃) δ = 7.92 (br s, 1H), 7.11–7.00 (m, 2H), 6.78 (ddd, *J* = 10.4, 6.9, 1.7 Hz, 1H), 6.35 (dd, *J* = 2.2, 0.8 Hz, 1H), 2.75 (t, *J* = 7.6 Hz, 2H), 1.77–1.66 (m, 2H), 1.51–1.38 (m, 2H), 0.99 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 155.9 (d, *J* = 245.2 Hz, C), 140.1 (C), 138.6 (d, *J* = 11.8 Hz, C), 121.4 (d, *J* = 7.6 Hz, CH), 117.8 (d, *J* = 22.4 Hz, C), 106.5 (d, *J* = 3.4 Hz, CH), 104.5 (d, *J* = 19.1 Hz, CH), 95.4 (CH), 31.3 (CH₂), 27.9 (CH₂), 22.5 (CH₂), 14.0 (CH₃); HRMS calcd for C₁₂H₁₄FN, 191.1110; found, 191.1106.

4-Chloro-2-phenyl-1*H*-indole (11a): Treatment of **8b** (170 mg, 0.5 mmol) with phenylacetylene (77 mg, 0.75 mmol), PdCl₂(PPh₃)₂ (10 mg, 3 mol%), CuI (5 mg, 5 mol%) and Et₂NH (54 mg, 0.75 mmol) in DMA (2 mL) for 3 h and then, with NaOH (200 mg, 5 mmol) for 4 h according to the general procedure, and purification by column chromatography (hexane/EtOAc, 7/1) on silica gel afforded **11a** (92 mg, 81%), whose spectroscopic data have been reported above.

2-Butyl-4-chloro-1*H*-indole (11b): Treatment of **8b** (339 mg, 1 mmol) with 1-hexyne (123 mg, 1.5 mmol), PdCl₂(PPh₃)₂ (21 mg, 3 mol%), CuI (9 mg, 5 mol%) and Et₂NH (109 mg, 1.5 mmol) in DMA (4 mL) for 2.5 h and then, with NaOH (400 mg, 10 mmol) for 3 h according to the general procedure, and purification by column chromatography (hexane/EtOAc, 8/1) on silica gel afforded **11b** (147 mg, 71%), whose spectroscopic data have been reported above.

4-Chloro-2-cyclohexenyl-1*H*-indole (11d): Treatment of **8b** (679 mg, 2 mmol) with 1-ethynylcyclohexene (320 mg, 3 mmol), PdCl₂(PPh₃)₂ (42 mg, 3 mol%), CuI (19 mg, 5 mol%) and Et₂NH (220 mg, 3 mmol) in DMA (6 mL) for 2 h and then, with NaOH (800 mg, 20 mmol) for 3 h according to the general procedure, and purification by column chromatography (hexane/EtOAc, 8/1) on silica gel afforded **11d** (379 mg, 82%), whose spectroscopic data have been reported above.

4-Chloro-1*H*-indole (11e):⁹ Treatment of **8b** (170 mg, 0.5 mmol) with trimethylsilylacetylene (73 mg, 0.75 mmol), PdCl₂(PPh₃)₂ (10 mg, 3 mol%), CuI (5 mg, 5 mol%) and Et₂NH (54 mg, 0.75 mmol) in DMA (2 mL) for 5.5 h and then, with NaOH (200 mg, 5 mmol) for 3 h according to the general procedure, and purification by column chromatography (hexane/EtOAc, 8/1) on silica gel afforded **11e** (46 mg, 61%), whose spectroscopic data have been reported above.

4-Chloro-2-(3-chlorophenyl)-1H-indole (11f): Treatment of **8b** (170 mg, 0.5 mmol) with 1-chloro-3-ethynylbenzene (102 mg, 0.75 mmol), PdCl₂(PPh₃)₂ (10 mg, 3 mol%), CuI (5 mg, 5 mol%) and Et₂NH (54 mg, 0.75 mmol) in DMA (2 mL) for 2 h and then, with NaOH (200 mg, 5 mmol) for 3 h according to the general procedure, and purification by column chromatography (hexane/EtOAc, 7/1) on silica gel afforded **11f** (98 mg, 75%) as a brown solid: R_f 0.63 (hexane/AcOEt, 3/1); mp 80–82 °C; ¹H NMR (300 MHz, CDCl₃) δ = 8.44 (br s, 1H), 7.62 (t, *J* = 1.7 Hz, 1H), 7.50 (dt, *J* = 7.5, 1.6 Hz, 1H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.32–7.24 (m, 2H), 7.17–7.08 (m, 2H), 6.92 (dd, *J* = 2.2, 0.7 Hz, 1H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 137.5 (C), 136.9 (C), 135.1 (C), 133.5 (C), 130.4 (CH), 128.1 (CH), 128.0 (C), 126.1 (C), 125.3 (CH), 123.39 (CH), 123.38 (CH), 120.3 (CH), 109.7 (CH), 99.4 (CH); EI-LRMS *m/z* 265 (M⁺+4, 13), 263 (M⁺+2, 62), 261 (M⁺, 100), 226 (13), 199 (30), 190 (35), 164 (30), 89 (49); HRMS calcd for C₁₄H₉Cl₂N, 261.0112; found, 261.0112.

4-Bromo-2-phenyl-1H-indole (12a): Treatment of **8c** (192 mg, 0.5 mmol) with phenylacetylene (77 mg, 0.75 mmol), PdCl₂(PPh₃)₂ (10 mg, 3 mol%), CuI (5 mg, 5 mol%) and Et₂NH (54 mg, 0.75 mmol) in DMA (2 mL) for 3 h and then, with NaOH (200 mg, 5 mmol) for 4 h according to the general procedure, and purification by column chromatography (hexane/EtOAc, 8/1) on silica gel afforded **12a** (66 mg, 49%), whose spectroscopic data have been reported above.

4-Bromo-2-butyl-1H-indole (12b): Treatment of **8c** (576 mg, 1.5 mmol) with 1-hexyne (182 mg, 2.25 mmol), PdCl₂(PPh₃)₂ (31 mg, 3 mol%), CuI (14 mg, 5 mol%) and Et₂NH (164 mg, 2.25 mmol) in DMA (6 mL) for 2 h and then, with NaOH (600 mg, 15 mmol) for 3 h according to the general procedure, and purification by column chromatography (hexane/EtOAc, 7/1) on silica gel afforded **12b** (207 mg, 55%), whose spectroscopic data have been reported above.

4-Bromo-2-(3-chlorophenyl)-1H-indole (12g): Treatment of **8c** (192 mg, 0.5 mmol) with 1-chloro-3-ethynylbenzene (102 mg, 0.75 mmol), PdCl₂(PPh₃)₂ (10 mg, 3 mol%), CuI (5 mg, 5 mol%) and Et₂NH (54 mg, 0.75 mmol) in DMA (2 mL) for 2 h and then, with NaOH (200 mg, 5 mmol) for 4 h according to the general procedure, and purification by column chromatography (hexane/EtOAc, 8/1) on silica gel afforded **12g** (73 mg, 48%) as a brown solid: R_f 0.38 (hexane/AcOEt, 4/1); mp 89–91 °C; ¹H NMR (300 MHz, CDCl₃) δ = 8.47 (br s, 1H), 7.67–7.64 (m, 1H), 7.55 (ddd, *J* = 7.6, 2.8, 1.3 Hz, 1H), 7.43–7.27 (m, 4H), 7.06 (td, *J* = 8.1, 1.2 Hz, 1H), 6.90–6.87 (m, 1H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 137.1 (C), 137.0 (C), 135.2 (C), 133.6 (C), 130.5 (CH), 129.9 (C), 128.2 (CH), 125.4 (CH), 123.8 (CH), 123.5 (CH), 123.4 (CH), 114.9 (C), 110.3 (CH), 101.2 (CH); EI-LRMS *m/z* 309 (M⁺+4, 23), 307 (M⁺+2, 100), 305 (M⁺, 80), 226 (16), 199 (34), 190 (74), 163 (60); HRMS calcd for C₁₄H₉BrClN, 304.9607; found, 304.9620.

Synthesis of 2-butyl-4-(furan-2-yl)-1H-indole (13):

Pre-milled Pd(OAc)₂ (2 mol%)/XPhos (4 mol%) and CsF (100 mg, 0.66 mmol) were added to a Schlenk tube under a nitrogen atmosphere, and the tube was evacuated and backfilled with nitrogen.¹⁰ Then, 4-chloroindole derivative **11b** (62 mg, 0.3 mmol), tributyl(furan-2-yl)stannane (118 mg, 0.33 mmol) and DME (0.8 cm³) were added to the tube. The reaction was heated to 80 °C with stirring for 3 h (the consumption of the starting material was monitored by GC-MS). After cooling to room temperature of the reaction vessel, the crude was filtered through zelite and washed with EtOAc (20 cm³). The solvent was concentrated under

reduced pressure and the residue was purified by column chromatography on silica gel (hexane/EtOAc, 7/1) to afford **13** (66 mg, 92%) as a white solid: R_f 0.43 (hexane/AcOEt, 6/1); mp 50–52 °C; ^1H NMR (300 MHz, CDCl_3) δ = 7.85 (br s, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.56–7.52 (m, 1H), 7.23–7.20 (m, 2H), 6.85 (d, J = 3.3 Hz, 1H), 6.75 (s, 1H), 6.60 (ddd, J = 3.3 Hz, 1.8, 0.6 Hz, 1H), 2.76 (t, J = 7.6 Hz, 2H), 1.79–1.68 (m, 2H), 1.52–1.39 (m, 2H), 1.01 (t, J = 7.3 Hz, 3H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 154.8 (C), 141.5 (CH), 141.0 (C), 136.6 (C), 124.4 (C), 122.1 (C), 121.0 (CH), 116.4 (CH), 111.6 (CH), 110.0 (CH), 106.2 (CH), 99.6 (CH), 31.4 (CH_2), 28.1 (CH_2), 22.5 (CH_2), 14.0 (CH_3); EI-LRMS m/z 239 (M^+ , 56), 196 (100), 167 (14), 154 (4); HRMS calcd for $\text{C}_{16}\text{H}_{17}\text{NO}$, 239.1310; found, 239.1319.

Synthesis of 2,4-Diphenyl-1H-indole (14):

4-Bromo-1H-indole derivative **12a** (81 mg, 0.3 mmol), phenylboronic acid (55 mg, 0.45 mmol) and $[\text{Pd}(\text{PPh}_3)_4]$ (10 mg, 3 mol%) were introduced in a Schlenk tube under a nitrogen atmosphere. Then, DME (5 cm^3) was added followed by the addition of Na_2CO_3 (48 mg, 0.45 mmol) in H_2O (2 cm^3). The reaction mixture was vigorously stirred and heated at 80 °C overnight (the progress of the reaction was monitored by GC-MS).^{11,12} Then, CH_2Cl_2 (10 cm^3) and H_2O were added to the cooled reaction mixture. The separated aqueous phase was extracted with CH_2Cl_2 ($3 \times 20 \text{ cm}^3$). The combined organic extracts were dried over anhydrous Na_2SO_4 , and evaporated under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc, 8/1) on silica gel to afford **14** (74 mg, 93%) as a white solid: R_f 0.48 (hexane/AcOEt, 4/1); mp 205–207 °C (lit.¹³ mp 209 °C); ^1H NMR (300 MHz, CDCl_3) δ = 8.42 (br s, 1H), 7.89–7.82 (m, 2H), 7.67 (d, J = 8.1 Hz, 2H), 7.61 (t, J = 7.7 Hz, 2H), 7.53–7.44 (m, 3H), 7.43–7.25 (m, 4H), 7.12 (d, J = 2.2 Hz, 1H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 141.3 (C), 138.3 (C), 137.3 (C), 134.5 (C), 132.2 (C), 129.1 (2 \times CH), 128.9 (2 \times CH), 128.7 (2 \times CH), 127.8 (CH), 127.6 (C), 127.1 (CH), 125.2 (2 \times CH), 122.7 (CH), 120.2 (CH), 110.2 (CH), 99.6 (CH); EI-LRMS m/z 269 (M^+ , 100), 190 (10), 165 (53), 133 (11), 77 (28); HRMS calcd for $\text{C}_{20}\text{H}_{15}\text{N}$, 269.1204; found, 269.1204.

Synthesis of 4-(hex-1-ynyl)-2-phenyl-1H-indole (15):

A mixture of 4-bromo-1H-indole derivative **12a** (81 mg, 0.3 mmol), 1-hexyne (37 mg, 0.45 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (12 mg, 6 mol%), CuI (6 mg, 10 mol%) and Et_2NH (33 mg, 0.45 mmol) in anhydrous DMF (3 cm^3) was stirred under a nitrogen atmosphere at 80 °C for 17 h (complete consumption of the starting material was monitored by GC-MS). Then, CH_2Cl_2 (20 cm^3) and aq HCl (20 cm^3 of a 0.5M solution) were added to the cooled reaction mixture. The separated aqueous phase was extracted with CH_2Cl_2 ($3 \times 15 \text{ cm}^3$). The combined organic layers were washed with water ($2 \times 40 \text{ cm}^3$), dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (hexane/EtOAc, 8/1) to afford **15** (63 mg, 77%) as a brown solid: R_f 0.42 (hexane/AcOEt, 5/1); mp 33–35 °C; ^1H NMR (300 MHz, CDCl_3) δ = 8.39 (br s, 1H), 7.69 (d, J = 7.3 Hz, 2H), 7.45 (t, J = 7.7 Hz, 2H), 7.33 (d, J = 7.3 Hz, 2H), 7.21 (d, J = 7.3 Hz, 1H), 7.11 (t, J = 7.7 Hz, 1H), 6.99–6.97 (m, 1H), 2.55 (t, J = 6.9 Hz, 2H), 1.75–1.63 (m, 2H), 1.62–1.50 (m, 2H), 1.00 (t, J = 7.2 Hz, 3H); ^{13}C NMR (75.4 MHz, CDCl_3) δ = 138.2 (C), 136.5 (C), 132.3 (C), 131.1 (C), 129.2 (2 \times CH), 128.0 (CH), 125.3 (2 \times CH), 123.9 (CH), 122.3 (CH), 115.8 (C), 110.7 (CH), 99.9 (CH), 93.2 (C), 79.3 (C), 31.2 (CH_2), 22.2 (CH_2), 19.6 (CH_2), 13.9 (CH_3); EI-LRMS m/z

273 (M^+ , 89), 258 (16), 244 (38), 230 (100), 202 (29), 127 (23); HRMS calcd for $C_{20}H_{19}N$, 273.1517; found, 273.1511.

Synthesis of 4-Bromo-3-((*Z*)-4-methyl-1,3-diphenylpenta-1,3-dienyl)-2-phenyl-1*H*-indole (**16**):

To a solution of 4-bromo-1*H*-indole derivative **12a** (42 mg, 0.155 mmol) and 4-methyl-1,3-diphenylpenta-1-yn-3-ol (42 mg, 0.17 mmol) in MeCN (2 cm³) was added *p*-toluenesulfonic acid monohydrate (13 mg, 10 mol%).¹⁴ The resulting mixture was heated at 80 °C for 5.5 h and monitored by GC-MS. The solvent was evaporated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (hexane/EtOAc, 10/1) to afford **16** (62 mg, 80%) as a white solid: R_f 0.36 (hexane/AcOEt, 5/1); mp 72–74 °C; ¹H NMR (300 MHz, CDCl₃) δ = 7.98 (br s, 1H), 7.55–7.48 (m, 4H), 7.39–7.23 (m, 7H), 7.05 (d, J = 7.8 Hz, 1H), 6.95 (d, J = 7.8 Hz, 1H), 6.82 (t, J = 7.8 Hz, 1H), 6.77–6.64 (m, 4H), 6.50 (t, J = 7.1 Hz, 1H), 1.43 (s, 6H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 144.2 (C), 141.3 (C), 136.91 (C), 136.86 (C), 134.9 (C), 134.5 (C), 134.1 (C), 133.3 (CH), 132.8 (C), 128.55 (2 \times CH), 128.53 (2 \times CH), 128.4 (2 \times CH), 127.8 (CH), 127.2 (2 \times CH), 126.94 (2 \times CH), 126.87 (C), 126.8 (CH), 126.2 (2 \times CH), 124.3 (CH), 124.0 (CH), 122.7 (CH), 115.1 (C), 113.3 (C), 109.4 (CH), 22.2 (CH₃), 21.0 (CH₃); EI-LRMS m/z 505 (M^+ +2, 37), 503 (M^+ , 36), 424 (41), 409 (72), 207 (100); HRMS calcd for $C_{32}H_{26}BrN$, 503.1249; found, 503.1255.

Synthesis of 4-chloro-2-phenyl-3-(phenylthio)-1*H*-indole (**17**):



Freshly powdered NaOH (48 mg, 1.2 mmol) was added to a solution of **9a** (125 mg, 0.4 mmol) in anhydrous DMA (3 cm³). The resulting mixture was heated under a nitrogen atmosphere for 5 h at 140 °C (until the cyclization was completed as monitored by GC-MS). Then, Ph₂S₂ (104 mg, 0.48 mmol) was added to the mixture and the reaction was stirred overnight at 140 °C. Then, CH₂Cl₂ (10 cm³) and aq HCl (10 cm³ of a 0.5M solution) were added to the cooled reaction mixture. The separated aqueous phase was extracted with CH₂Cl₂ (3 \times 10 cm³). The combined organic layers were washed with water (2 \times 30 cm³), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (hexane/EtOAc, 5/1) to afford **17** (105 mg, 78%) as a white solid: R_f 0.40 (hexane/AcOEt, 5/1); mp 131–133 °C; ¹H NMR (300 MHz, CDCl₃) δ = 8.70 (br s, 1H), 7.66 (dd, J = 6.6, 2.9 Hz, 2H), 7.43–7.38 (m, 3H), 7.36–7.29 (m, 1H), 7.26–7.05 (m, 7H); ¹³C NMR (75.4 MHz, CDCl₃) δ = 144.3 (C), 141.4 (C), 137.3 (C), 131.0 (C), 129.2 (CH), 128.9 (2 \times CH), 128.7 (4 \times CH), 127.0 (C), 126.8 (C), 125.3 (2 \times CH), 124.6 (CH), 123.7 (CH), 122.8 (CH), 110.2 (CH), 98.8 (C); EI-LRMS m/z 337 (M^+ +2, 22), 335 (M^+ , 51), 299 (16), 267 (15), 223 (100), 190 (12), 121 (22), 119 (23), 77 (86), 51 (67); HRMS calcd for $C_{20}H_{14}ClNS$, 335.0535; found, 335.0534.

REFERENCES:


- (1) B. McKittrick, A. Failli, R. J. Steffan, R. M. Soll, P. Hughes, J. Schmid, A. A. Asselin, C. C. Shaw, R. Noureldin, G. Gavin, *J. Heterocycl. Chem.*, 1990, **27**, 2151.
- (2) C. E. Stauffer, *J. Am. Chem. Soc.*, 1972, **94**, 7887.
- (3) Y.-Q. Fang, M. Lautens, *Org. Lett.*, 2005, **7**, 3549.

- (4) R. Sanz, M. P. Castroviejo, Y. Fernández, F. J. Fañanás, *J. Org. Chem.*, 2005, **70**, 6548.
- (5) Developed by Kondo and Uchiyama for the chemoselective deprotonative zincation of functionalized aromatic compounds: (a) Y. Kondo, M. Shilai, M. Uchiyama, T. Sakamoto, *J. Am. Chem. Soc.*, 1999, **121**, 3539; (b) M. Uchiyama, T. Miyoshi, Y. Kajihara, T. Sakamoto, Y. Otani, T. Ohwada, Y. Kondo, *J. Am. Chem. Soc.*, 2002, **124**, 8514; (c) R. Sanz, M. P. Castroviejo, V. Guilarte, A. Pérez, F. J. Fañanás, *J. Org. Chem.*, 2007, **72**, 5113.
- (6) H. H. Hodgson, A. Kershaw, *J. Chem. Soc.*, 1929, 2917.
- (7) (a) J. F. W. McOmie, D. E. West, *Org. Synth., Collect. Vol. 5*, 1973, 412. (b) A. J. Peat, S. L. Buchwald, *J. Am. Chem. Soc.*, 1996, **118**, 1028.
- (8) K. Nishijima, T. Shinkawa, M. Ito, H. Nishida, I. Yamamoto, Y. Onuki, H. Inaba, S. Miyano, *J. Med. Chem.*, 1998, **33**, 763.
- (9) Commercially available.
- (10) J. R. Naber, S. L. Buchwald, *Adv. Synth. Catal.*, 2008, **350**, 957.
- (11) L. Brandsma, S. F. Vasilevsky, H. D. Verkruijsse, in *Application of Transition Metal Catalysts in Organic Synthesis*; Springer-Verlag, Berlin 1998; Ch. 11.
- (12) B. Witulski, J. R. Azcon, C. Alayrac, A. Arnautu, V. Collot, S. Rault, *Synthesis*, 2005, 771.
- (13) C. F. Allen, M. R. Gilbert, D. M. Young, *J. Org. Chem.*, 1937, **2**, 227.
- (14) R. Sanz, M. Gohain, D. Miguel, A. Martínez, F. Rodríguez, *Synlett*, 2009, 1985.



¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):





¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):





5a




¹³C-NMR (75.4 MHz, CDCl₃):





^1H -NMR (300 MHz, CDCl_3):




^{13}C -NMR (75.4 MHz, CDCl_3):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





^1H -NMR (300 MHz, CDCl_3):




^{13}C -NMR (75.4 MHz, CDCl_3):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




$^1\text{H-NMR}$ (300 MHz, CDCl_3):




$^{13}\text{C-NMR}$ (75.4 MHz, CDCl_3):




¹H-NMR (300 MHz, CDCl₃):





10c




¹³C-NMR (75.4 MHz, CDCl₃):





^1H -NMR (300 MHz, CDCl_3):




^{13}C -NMR (75.4 MHz, CDCl_3):




¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




$^1\text{H-NMR}$ (400 MHz, CDCl_3):




10f




$^{13}\text{C-NMR}$ (100.6 MHz, CDCl_3):




¹H-NMR (300 MHz, CDCl₃):





11a




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):





11d




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):




12b




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):





12c




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):





¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):





14




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):




¹³C-NMR (75.4 MHz, CDCl₃):




¹H-NMR (300 MHz, CDCl₃):





16



¹³C-NMR (75.4 MHz, CDCl₃):



¹H-NMR (300 MHz, CDCl₃):



¹³C-NMR (75.4 MHz, CDCl₃):

